CNN —
Lecanemab, a monoclonal antibody therapy for Alzheimer's disease, delays the progression of cognitive deterioration by 27% when compared to a placebo, according to a report released on Tuesday by the pharmaceutical companies Biogen and Eisai.
The medicine demonstrated "target engagement" with decreased amyloid levels, a protein that is one of the hallmarks of Alzheimer's, as well as favorable impacts on cognition and the capacity to carry out daily tasks as compared to a placebo in a Phase 3 worldwide clinical trial.According to Eisai CEO Haruo Naito, "We feel that helping to ease these responsibilities will favorably benefit society as a whole." Additionally, the findings of the lecanemab Clarity AD trial support the amyloid hypothesis, according to which one of the primary causes of Alzheimer's disease is the aberrant buildup of A in the brain.
The trial results, according to Dr. Richard Isaacson, head of the Alzheimer's Prevention Clinic at Florida Atlantic University's Schmidt College of Medicine's Center for Brain Health, are not evidence in favor of the amyloid theory, he told CNN.
"It demonstrates that this medication is effective in patients with a specific level of amyloid in their brains at a specific stage of the disease. No, not in terms of utilizing a drug to demonstrate a mechanism. Alzheimer's is an extremely diverse illness.
But he claims that does not lessen the trial's possible importance."In the past, lowering amyloid in the brain hasn't always been associated with benefits in clinical outcomes or cognition. Every endpoint in this trial had a good result. Never before has such occurred.
Lecanemab adverse effects were reported by 21.3% of trial participants overall, although Isaacson advises that patients on this kind of treatment must be closely watched at all times. He claims that symptomatic side effects are a more crucial metric.
"When this medication is administered properly, the side effects are manageable, and the adverse effects are generally avoidable," he stated.
In the drug-controlled experiment, the rate of symptomatic ARIA-E, or brain swelling, was 2.8% in those taking the medication and 0% in those using a placebo. Brain hemorrhage, iron buildup in tissue, and symptomatic ARIA-H occurred at a rate of 0.7% in the medication group and 0.2% in the placebo group, respectively.
In light of the findings, the Alzheimer's Association expressed optimism.
The medication "has the potential to affect the trajectory of the illness in a clinically meaningful way for persons in the early stages of Alzheimer's," the association stated in a statement. These findings suggest that lecanamab may prolong a person's ability to engage in everyday activities, maintain their independence, and make decisions about their future medical treatment. Treatments that provide these advantages to people with early-stage Alzheimer's dementia and moderate cognitive impairment (MCI) are just as important as those that prolong the lives of those with other terminal diseases."I'm imagining a scenario where, in the years to come, this will, this type of treatment will be one of the many options in our toolbox in the management of Alzheimer's disease," Isaacson concurred.
The corporations claim they intend to publish the results in a peer-reviewed journal and to submit the information in order to request clearance from US regulatory agencies by the end of March, despite the fact that the conclusions are based only on preliminary data.
Another Alzheimer's medication, Aduhelm, was created by Biogen and was controversially authorized by the FDA in June 2021. Aduhelm was the first brand-new Alzheimer's medication licensed in nearly 20 years, yet concerns remained regarding its effectiveness and price. Its eligibility was swiftly restricted by the FDA, and given the lack of clarity surrounding its outcomes, it's unknown how many doctors will recommend it.
Aduhelm was also the major factor for the substantial rise in 2022 Medicare Part B premiums and the April Medicare coverage restrictions.
[zombify_post]
0 Comments